Compare Coursera Inc (COUR) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Coursera Inc vs GSK plc — how do they compare? Coursera Inc trades at $5.2 (market cap $1.39B), while GSK plc trades at $46.54 (market cap $91.88B). The key difference: GSK plc is far larger — about 66.1× Coursera Inc's market cap, and GSK plc pays a 3.9% dividend while Coursera Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Coursera Inc for 47 Days and GSK plc for 93 Days on average.
| COUR | GSK | |
|---|---|---|
Market Cap | $1.39B | $91.88B |
Volume | 9,728,980 | 7,730,529 |
Sector | Consumer Staples | Health |
52-Week High | $10.73 | $61.18 |
52-Week Low | $4.64 | $43.24 |
Typical Hold Time | 47 Days | 93 Days |
Enterprise Value | $648.49M | $111.88B |
Dividend Yield | — | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coursera (COUR) trades at $5.16, up 0.98% with a mixed technical picture showing bullish overall signals but bearish moving averages. The company shows improving revenue growth from $524M in 2022 to $758M in 2025, though it remains unprofitable with a -15.39% net margin. Recent news highlights strong institutional interest with Deutsche Bank acquiring 1.7M shares and positive analyst sentiment with 52.94% buy ratings.
The stock presents a growth opportunity with 44% subscriber growth and $85M synergy targets, but faces execution risks from ongoing losses and competitive pressures. With a consensus price target of $7.40 representing 43% upside, the bullish analyst outlook contrasts with fundamental profitability challenges that require careful monitoring.
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Coursera Inc
Coursera Inc is a global online learning platform that offers anyone, anywhere access to online courses and degrees from world-class universities and companies. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The platform will contain a catalog of high-quality content and credentials, content developed by leading university and industry partners, data and machine learning drive personalized Learning, effective marketing, and skills Benchmarking and others.
Read more on COUR →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
